FDA Accepts New Drug Application for Zanubrutinib Combination for R/R Follicular Lymphoma
Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.